Literature DB >> 17192257

Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.

Josef Wissing1, Lothar Jänsch, Manfred Nimtz, Guido Dieterich, Renate Hornberger, György Kéri, Jürgen Wehland, Henrik Daub.   

Abstract

Protein kinases constitute a large superfamily of enzymes with key regulatory functions in nearly all signal transmission processes of eukaryotic cells. However, due to their relatively low abundance compared with the vast majority of cellular proteins, currently available proteomics techniques do not permit the comprehensive biochemical characterization of protein kinases. To address these limitations, we have developed a prefractionation strategy that uses a combination of immobilized low molecular weight inhibitors for the selective affinity capture of protein kinases. This approach resulted in the direct purification of cell type-specific sets of expressed protein kinases, and more than 140 different members of this enzyme family could be detected by LC-MS/MS. Furthermore the enrichment technique combined with phosphopeptide fractionation led to the identification of more than 200 different phosphorylation sites on protein kinases, which often remain occluded in global phosphoproteome analysis. As the phosphorylation states of protein kinases can provide a readout for the signaling activities within a cellular system, kinase-selective phosphoproteomics based on the procedures described here has the potential to become an important tool in signal transduction analysis.

Mesh:

Substances:

Year:  2006        PMID: 17192257     DOI: 10.1074/mcp.T600062-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  40 in total

1.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

Review 2.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Protein kinase affinity reagents based on a 5-aminoindazole scaffold.

Authors:  Ratika Krishnamurty; Amanda M Brock; Dustin J Maly
Journal:  Bioorg Med Chem Lett       Date:  2010-10-21       Impact factor: 2.823

4.  Large-scale proteomics analysis of the human kinome.

Authors:  Felix S Oppermann; Florian Gnad; Jesper V Olsen; Renate Hornberger; Zoltán Greff; György Kéri; Matthias Mann; Henrik Daub
Journal:  Mol Cell Proteomics       Date:  2009-04-15       Impact factor: 5.911

5.  Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression.

Authors:  Kalyan Dulla; Henrik Daub; Renate Hornberger; Erich A Nigg; Roman Körner
Journal:  Mol Cell Proteomics       Date:  2010-01-23       Impact factor: 5.911

6.  Quantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from Listeria monocytogenes.

Authors:  Tobias Reinl; Manfred Nimtz; Claudia Hundertmark; Thorsten Johl; György Kéri; Jürgen Wehland; Henrik Daub; Lothar Jänsch
Journal:  Mol Cell Proteomics       Date:  2009-07-29       Impact factor: 5.911

7.  Proteomics strategy for quantitative protein interaction profiling in cell extracts.

Authors:  Kirti Sharma; Christoph Weber; Michaela Bairlein; Zoltán Greff; György Kéri; Jürgen Cox; Jesper V Olsen; Henrik Daub
Journal:  Nat Methods       Date:  2009-09-13       Impact factor: 28.547

8.  Affinity reagents that target a specific inactive form of protein kinases.

Authors:  Pratistha Ranjitkar; Amanda M Brock; Dustin J Maly
Journal:  Chem Biol       Date:  2010-02-26

9.  Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays.

Authors:  Mikhail M Savitski; Frank Fischer; Toby Mathieson; Gavain Sweetman; Manja Lang; Marcus Bantscheff
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-25       Impact factor: 3.109

Review 10.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.